Ocuphire Pharma Inc
NASDAQ:OCUP

Watchlist Manager
Ocuphire Pharma Inc Logo
Ocuphire Pharma Inc
NASDAQ:OCUP
Watchlist
Price: 1.13 USD -3.42% Market Closed
Market Cap: 35.7m USD

OCUP's latest stock split occurred on Nov 6, 2020

The company executed a 1-for-4 stock split, meaning that for every 4 shares held, investors received 1 new share.

Before the split, OCUP traded at 1.81 per share. Afterward, the share price was about 6.

The adjusted shares began trading on Nov 6, 2020. This was OCUP's 4th stock split, following the previous one in Apr 12, 2019.

Last Splits:
Nov 6, 2020
1-for-4
Apr 12, 2019
1-for-12
May 5, 2017
1-for-10
May 16, 2005
1-for-100
Pre-Split Price
7.24 1.81
Post-Split Price
6
Before
After
Last Splits:
Nov 6, 2020
1-for-4
Apr 12, 2019
1-for-12
May 5, 2017
1-for-10
May 16, 2005
1-for-100

Ocuphire Pharma Inc
Stock Splits History

OCUP Stock Splits Timeline
Nov 6, 2020
Nov 6, 2020
Split 1-for-4
/0.25
Pre-Split Price
7.24 1.81
Post-Split Price
6
Before
After
Apr 12, 2019
Apr 12, 2019
Split 1-for-12
/0.083333333333333
Pre-Split Price
22.0752 0.4599
Post-Split Price
22.44
Before
After
May 5, 2017
May 5, 2017
Split 1-for-10
/0.1
Pre-Split Price
188.16 0.392
Post-Split Price
184.8
Before
After
May 16, 2005
May 16, 2005
Split 1-for-100
/0.01
Pre-Split Price
720 0.015
Post-Split Price
1 440
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Jan 20, 2026
Linius Technologies Ltd
OTC:LNNTF
1-for-100
/100
0.0001 0.0001 USD N/A
Jan 20, 2026
Lotus Resources Ltd
OTC:LTSRF
1-for-11
/11
0.137 0.137 USD N/A
Jan 15, 2026
Amcor PLC
NYSE:AMCR
1-for-5
/5
8.4 8.4 USD N/A
Jan 8, 2026
Sumitomo Realty & Development Co Ltd
OTC:SURYY
2-for-1
x2
25.635 25.635 USD N/A
Jan 7, 2026
Deutsche Effecten und Wechsel Beteiligungsgesellschaft AG
SWB:EFF
1-for-10
/10
0.35 0.35 EUR N/A
Load More

Ocuphire Pharma Inc
Glance View

Market Cap
35.7m USD
Industry
Pharmaceuticals

Ocuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. The company is headquartered in Farmington Hills, Michigan and currently employs 8 full-time employees. The company went IPO on 2004-11-30. Its products include Nyxol Eye Drops and APX3330. The Nyxol Eye Drops is a once-daily preservative-free eye drop formulation of phentolamine mesylate designed to reduce pupil diameter and improve visual acuity. Nyxol is being developed for several indications, including night vision disturbances, reversal of pharmacologically induced mydriasis and presbyopia. The APX3330, is a twice-a-day oral tablet, designed to inhibit angiogenesis and inflammation pathways relevant to retinal and choroidal vascular diseases. Its pre-clinical products are APX2009 and APX2014. APX3330 is in Phase II trial for the treatment of patients with diabetic retinopathy (DR), including moderately severe non-proliferative DR and mild proliferative DR, as well as patients with diabetic macular edema (DME) without loss of central vision.

OCUP Intrinsic Value
2.09 USD
Undervaluation 46%
Intrinsic Value
Price
Back to Top